Navigation Links
Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Date:2/28/2008

RICHMOND, Va., Feb. 28 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that on February 27, 2008, it received a letter from the Nasdaq Listings Qualifications Panel (the "Panel") stating that the Panel has determined to transfer the listing of the Company's shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the open of the market on Friday, February 29, 2008. The Nasdaq Capital Market is one of the three market tier designations for Nasdaq-listed stock, and presently includes over 500 companies. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market. It is not related to, nor does it operate similarly to the over-the-counter markets, including the OTCBB and Pink Sheets. Securities listed on the Nasdaq Capital Market satisfy all applicable qualification requirements for Nasdaq securities and all companies listed on the Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards. Insmed's trading symbol will remain "INSM."

The determination is the result of a hearing between Insmed and the Panel on January 24, 2008, regarding Insmed's non-compliance with Marketplace Rule 4405(a)(5), the minimum bid price requirement of $1.00 per share, a continued listing requirement of Nasdaq. Once Insmed's securities are transferred to the Nasdaq Capital Market, it will have until June 12, 2008, to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Should the Company not regain compliance by this date, its shares shall be delisted from the Nasdaq Capital Market. Following such delisting, the Company's common stock could be eligible to trade on the OTCBB or the Pink Sheets.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., REDWOODCITY,Calif.,Nov.24/PRNewswire-FirstCal...dthatRandyScott,GenomicHealth,sExecutiveChairman,w...ferenceinNewYorkCityonTuesday,December1,2009at10:0...vedwebcastofthepresentation,visittheInvestorRelati...or.genomichealth.com .Pleaseconnecttothewebsiteatl...
(Date:11/24/2009)... Chemical Abstracts Service ...reports that China,s patent office is now the worl...ons in chemistry. China trailed Japan,s patent off...(WIPO), and the United States Patent and Trademark... the USPTO in 2005, WIPO in 2006, and exceeded Jap...
(Date:11/23/2009)...HAMPAIGN, Ill. You can think of it as origami ve...sity of Illinois have developed a technique for fa...licon structures from thin films by coupling photo...apillary interactions. , The films, only a few mi...not possible with thicker pieces of the same mater...
(Date:11/23/2009)..., INCLINEVILLAGE,Nev.,Nov.23/PRNewswire-FirstCa...ouncedthatNASDAQhasestablishedNovember27,2009asthe...tockholdersresultingfromthesecuritizationtransacti...nDecember15,2009toallstockholdersofrecordonthereco...rshareamountofthedividendat$1.67pershareofcommonst...
Breaking Biology Technology:Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Water droplets direct self-assembly process in thin-film materials 2PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2
...., Jan. 13 Nektar Therapeutics,(Nasdaq: NKTR ) ... 2 clinical,trial of NKTR-102 in platinum-resistan...been obtained and dosing will begin shortly in two...evaluate NKTR-102 versus irinotecan in,second-line...ation, and a,Phase 2 study in metastatic breast ca...
.... 13 Burnham Institute for Medical Research (Burn...greement with Johnson & Johnson Pharmaceutical...he agreement is Burnham,s first broad-based partne...der this multi-year agreement, Burnham will provid...screening technologies to investigate certain drug...
...., Jan. 13 Neurobiological,Technologies, Inc. (Na...owing a,detailed analysis of the recent interim re...any has decided not to develop Viprinex further fo... was recently studied in a,clinical trial to deter...,outcome when given within six hours of a stroke, ...
Other Biology Technology:First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 2First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 3First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 4Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2Neurobiological Technologies Announces Suspension of Viprinex Development 2Neurobiological Technologies Announces Suspension of Viprinex Development 3
(Date:11/25/2009)...ach, may be used to boost resistance to, or slow, ...l of Medicine researchers report in a study publis...nce . , Parkinson,s disease is caused by a degen...rain known as the substantia nigra, which is respo...n of dopamine in late-stage Parkinson,s causes sym...
(Date:11/25/2009)...eath Research Laboratory in the University of Haif...estigious Johnson & Johnson Focused Funding grant ... damage in Parkinson,s disease. The award, which i...novation and excellence in science, was announced ...th at an event at the Hyatt Regency Hotel in New J...
(Date:11/25/2009)...fessors recently received funding from the Nationa...neficial to understanding the environment. The thr...d, assistant professor in the Department of Biolog...eparate research projects. , His first project, ...nd Functions from the Leaf to the Landscape," will...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Kent State University professors focus research on the environment with grants totaling $890,000 2Rigel to Present at Jefferies Healthcare Conference 48415 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 5Oramed Pharmaceuticals to Present at the 8th National Life Science 26 Technology Week ILSI BIOMED Conference Israel 2009 4583 1Oramed Pharmaceuticals to Present at the 8th National Life Science 26 Technology Week ILSI BIOMED Conference Israel 2009 4583 2
... subjects to operate a robot-controlled joystick, ...er the brain "learns" to control certain muscle mo...son over the long haul. The results, the investiga...r people who have lost motor abilities to brain in... the May 23 issue of PLoS Biology, the researchers...
...archers have found a group of cells in the intesti...lls, cells that help fight infection. , The resear...journal Immunity, released today. , "This connect... will help in studying and developing treatments f...m," said Stephen McSorley, Ph.D., professor of med...
...t four factors, researchers have successfully indu...or adult mice to behave like embryonic stem cells....ediate early publication of the journal Cell, publ...rchers designate "induced pluripotent stem cells" ...haracteristics typical of embryonic stem cells, th...
Other Biology News:New approach to vaccine development provides potent, long-lasting immunity 2New approach to vaccine development provides potent, long-lasting immunity 3With few factors, adult cells take on character of embryonic stem cells 2
Mouse Anti-Mouse Qa-2 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone 695H1-9-9 from BioLegend
27-mer duplex from B-Bridge International
Propidium Iodide Buffer from BioLegend
Luminex 100 Instrument System from Upstate
Biology Products: